Angiotensin‐converting enzyme 2 (ACE2) has been identified as the main receptors for SARS‐CoV and SARS‐CoV‐2. Soluble ACE2 (sACE2) can bind to the S‐protein and thus inhibit SARS‐CoV infection. The use of sACE2 has the potential to effectively treat acute lung injury, thereby reducing mortality. In addition, sACE2 can potentially be effective in the treatment of SARS‐CoV‐2 infection and the subsequent destruction of other organs with ACE2 receptors, such as the heart, kidney, and testes.
Based on the solubility nhancing effect of CDs it was postulated that the formation of a complex of CD and sACE2 can effectively improve the water solubility of sACE2 so it meets the requirements for drug atomization inhalation. The inclusion conjugates release sACE2 after entering the body via atomization or other drug delivery means, and the released sACE2 combines with SARS‐CoV‐2 S‐proteins to block the virus’s ability to infect and destroy human cells.
sACE2 can be aerosolized so that it can be inhaled directly into the lungs, thus preventing inhaled coronavirus from infecting lung cells and stopping replicated coronaviruses released from already‐infected lung cells from infecting healthy lung cells. In addition, intravenous infusion of sACE2 can effectively prevent the coronavirus from infecting and damaging other organs that have ACE2 receptors. Eye drops and nasal drops made from CD‐sACE2 inclusion compounds can directly block coronavirus infection through the conjunctiva and nasal cavity.
Sun, P., Lu, X., Xu, C., (…), Sun, W., Xi, J. (2020) CD-sACE2 inclusion compounds: An effective treatment for coronavirus disease 2019 (COVID-19). Journal of Medical Virology 92(10), pp. 1721-1723.